Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(21):1638-1640; doi:10.1093/jnci/djg095
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ando, Y.
Right arrow Articles by Sasaki, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ando, Y.
Right arrow Articles by Sasaki, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

CORRESPONDENCE

Re: Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001

Yuichi Ando, Tomoko Ohtsu, Masahiko Ando, Fumiyoshi Ohyanagi, Fumio Nagashima, Masaru Narabayashi, Nagahiro Saijo, Yasutsuna Sasaki

Affiliations of authors: Saitama Medical School, Saitama, Japan (YA, FO, FN, MN, YS); National Cancer Center Hospital East, Chiba, Japan (TO); Kyoto University, Kyoto, Japan (MA); National Cancer Center Hospital, Tokyo, Japan (NS).

Correspondence to: Yuichi Ando, MD, PhD, Department of Clinical Oncology, Saitama Medical School, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan (e-mail: yando@saitama-med.ac.jp).

The first 10% of the full text of this article appears below.

In a recent article in the Journal, Baker et al. (1) reported that body surface area (BSA)-based dosing was not associated with a decrease in interpatient variability in the pharmacokinetics of most anticancer agents. Interestingly, a BSA-based dosing strategy was associated with a decrease in interpatient variability in paclitaxel clearance, a finding that has been recently validated in a prospective study (2). Because the pharmacokinetic variability among patients reflects . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?